PMID- 16446343
OWN - NLM
STAT- MEDLINE
DCOM- 20060213
LR  - 20061115
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 24
IP  - 4
DP  - 2006 Feb 1
TI  - Prognostic value of International Neuroblastoma Pathology Classification in 
      localized resectable peripheral neuroblastic tumors: a histopathologic study of 
      localized neuroblastoma European Study Group 94.01 Trial and Protocol.
PG  - 695-9
AB  - PURPOSE: To assess the prognostic value of clinical, biologic, and morphologic 
      data in peripheral neuroblastic tumors, International Neuroblastoma Staging 
      System (INSS) stages 2A and 2B MYCN nonamplified, a multinational protocol 
      entitled Localized Neuroblastoma European Study Group trial 94.01, with a trial 
      of surgery as the only treatment, was initiated in 1995. We present the 
      prognostic value of the revised International Neuroblastoma Pathology 
      Classification (INPC) applied to the patients included in this protocol until its 
      closure in 1999. MATERIALS AND METHODS: A total of 120 neuroblastic tumors from 
      trial patients were reviewed by the European International Society of Pediatric 
      Oncology neuroblastoma pathology panel and assigned to a favorable or unfavorable 
      prognostic category according to the INPC guidelines. Overall survival and 
      relapse-free survival (RFS) were estimated by the Kaplan-Meier method and 
      compared by the log-rank test. RESULTS: A total of 115 of 120 patients were 
      assessable and were assigned to the favorable (90 patients; 78.3%) or unfavorable 
      (25 patients; 21.7%) category. The 60-month survival rate was 97.7% in favorable 
      patients compared with 73.8% in unfavorable patients (P = .0002). RFS analysis 
      showed a 60-month relapse rate of 13.4% and 32% in favorable and unfavorable 
      patients (P < .025), respectively. Statistical analysis demonstrated a 
      significant association of unfavorable INPC category and high lactate 
      dehydrogenase level (P < .045). CONCLUSION: This European study shows for the 
      first time that the INPC prognostic categorization has a significant impact on 
      outcome prediction in INSS stage 2 localized peripheral neuroblastic tumors.
FAU - Navarro, Samuel
AU  - Navarro S
AD  - Departamento de Patologia, Universidad de Valencia, Spain. samuel.navarro@uv.es
FAU - Amann, Gabriele
AU  - Amann G
FAU - Beiske, Klaus
AU  - Beiske K
FAU - Cullinane, Catherine J
AU  - Cullinane CJ
FAU - d'Amore, Emanuele S G
AU  - d'Amore ES
FAU - Gambini, Claudio
AU  - Gambini C
FAU - Mosseri, Veronique
AU  - Mosseri V
FAU - De Bernardi, Bruno
AU  - De Bernardi B
FAU - Michon, Jean
AU  - Michon J
FAU - Peuchmaur, Michel
AU  - Peuchmaur M
CN  - European Study Group 94.01 Trial and Protocol
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
SB  - IM
MH  - Disease-Free Survival
MH  - Europe
MH  - Ganglioneuroblastoma/pathology
MH  - Humans
MH  - L-Lactate Dehydrogenase/blood
MH  - Neuroblastoma/*classification/enzymology/*pathology/surgery/therapy
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2006/02/01 09:00
MHDA- 2006/02/14 09:00
CRDT- 2006/02/01 09:00
PHST- 2006/02/01 09:00 [pubmed]
PHST- 2006/02/14 09:00 [medline]
PHST- 2006/02/01 09:00 [entrez]
AID - 24/4/695 [pii]
AID - 10.1200/JCO.2004.00.8631 [doi]
PST - ppublish
SO  - J Clin Oncol. 2006 Feb 1;24(4):695-9. doi: 10.1200/JCO.2004.00.8631.